Furthermore, HER3 is a key player in tumor cell resistance to EGFR- and HER2-targeted therapies, particularly in pancreatic cancer where it regulates EGFR signaling by modulating the response to erlotinib or cetuximab [13]. This evidence concerns the gene EGFR and neoplasm.